EX-99.1 2 dp10732_ex9901.htm
Exhibit 99.01
Hampshire International Business Park
Chineham  Basingstoke
Hampshire RG24 8EP
United Kingdom
Tel +44 (0)1256 894000
Fax +44 (0)1256 894708
www.shire.com
   
   
Press Release
  
 

Basingstoke, UK and Philadelphia, US – July 24, 2008 – Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Shire Limited

2. Reason for the notification
State
Yes/No
An acquisition or disposal of voting rights
Yes
An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
  
An event changing the breakdown of voting rights
  
Other (please specify):  New Exemption DTR 5.1.3 (4) & DTR 5.1.5 (1)
Yes

3. Full name of person(s) subject to the notification obligation:
The Goldman Sachs Group Inc
4. Full name of shareholder(s) (if different from 3.):
Goldman, Sachs & Co.,
Goldman Sachs Financial Markets L.L.C.,
Spear, Leeds & Kellogg Specialists L.L.C.
5. Date of the transaction (and date on which the threshold is crossed
or reached if different):
21 July 2008
6. Date on which issuer notified:
23 July 2008
7. Threshold(s) that is/are crossed or reached:
3%
8. Notified details:
  

A: Voting rights attached to shares

Class/type of
shares
 if possible using
 the ISIN CODE
Situation previous to
the Triggering
transaction
Resulting situation after the triggering
transaction
 
Number
of
Shares
Number
of
Voting
Rights
Number
of
shares
Number of voting
rights
% of voting
rights
     
Direct
Direct
Indirect
Direct
Indirect
US82481R1068
  
Below 3%
  
341,958
 (113,986
ADRs)
16,910,901 (5,636,967
ADRs)
0.061%
3.023%


Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX



B: Financial Instruments

Resulting situation after the triggering transaction

Type of
financial
instrument
Expiration
date
Exercise/Conversion
Period/ Date
Number of voting
rights that may be
acquired if  the instrument
is exercised/converted
% of voting
rights
         


Total (A+B)
  
Number of voting rights
% of voting rights
17,252,859
3.08%


9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:

The interest in 179,931 shares arose from a beneficial interest held by Goldman, Sachs & Co. (“GS&Co.”), a direct subsidiary of GS Inc of  59,977 American Depositary Receipts (“ADRs”). These ADRs are, or will be, held at the Depositary Trust Company of New York (“DTC”).
 
The interest in 16,850,388 shares arose from an interest held by Goldman, Sachs & Co., a wholly-owned direct subsidiary of GS Inc, acting as custodian for its customers of 5,616,796 American Depositary Receipts (“ADRs”). These ADRs are, or will be, held at the Depositary Trust Company of New York (“DTC”).
 
The interest in 60,513 shares arose from an interest held by Goldman, Sachs & Co., a wholly-owned direct subsidiary of GS Inc, acting as discretionary manager of 20,171 American Depositary Receipts (“ADRs”). These ADRs are, or will be, held at the Depositary Trust Company of New York (“DTC”).
 
The interest in 45,942 shares arose from a beneficial interest held by Goldman Sachs International, a wholly-owned indirect subsidiary of GS Inc of 15,314 American Depositary Receipts (“ADRs”). These ADRs are, or will be, held at the Depositary Trust Company of New York (“DTC”).
 
The interest in 106,998 shares arose from a beneficial interest held by Goldman Sachs Financial Markets L.L.C.  of 35,666 American Depositary Receipts (“ADRs”). These ADRs are, or will be, held at the Depositary Trust Company of New York (“DTC”).
 
The interest in 9,087 shares arose from a beneficial interest held by Spear, Leeds & Kellogg Specialists LLC, a direct subsidiary of GS Inc of 3,029 American Depositary Receipts (“ADRs”). These ADRs are, or will be, held at the Depositary Trust Company of New York (“DTC”).
 
Proxy Voting:


10. Name of the proxy holder:
N/A
11. Number of voting rights proxy holder will cease to hold:
N/A
12. Date on which proxy holder will cease to hold voting rights:
N/A

13. Additional information:
General Email Contact: shareholderdisclosures@gs.com
14. Contact name:
Sean Rogers/Alan Cox
 

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
 
15. Contact telephone number:
0207-552-9205 / 0207-774 -8774

Contact at Shire Limited: Tony Guthrie, Deputy Company Secretary, 01256 894746
 
 
For further information please contact:

Investor Relations
Cléa Rosenfeld (Rest of the World)
+44 1256 894 160
 
Eric Rojas (North America)
+1 484 595 8252

Notes to editors

SHIRE LIMITED

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.  Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.
 
 
 

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX